Philip Scheltens (Edmond Sadaka/Sipa via AP Images)
January 14, 2021 11:04 AM EST
Financing

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

Nicole DeFeudis

Editor

Big Phar­ma has re­treat­ed from neu­ro­science over the past sev­er­al years, aban­don­ing or trim­ming back pro­grams af­ter fac­ing set­backs in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times